Harmonizing PBMC Isolation Across Multi-Center Clinical Trials
- No Comments
In a Phase 2 or Phase 3 trial, you might have twenty different clinical sites collecting blood. If Site A uses a different centrifuge speed than Site B, or if Site C leaves the blood on the bench for four hours longer than Site D, your downstream data will be incredibly noisy.
Site-to-Site Variability is a major confounding factor in immunogenicity studies. To generate clean data that meets rigorous FDA Bioanalytical Method Validation Guidelines, sponsors must harmonize the isolation process.
The Central Lab vs. The Wild West
There are two primary ways to solve the problem of variability:
- Centralized Processing: Ship fresh blood directly to a central laboratory for consistent isolation by the same team, using the same equipment. This is where programs like our Same-Day PBMC Processing Services shine.
- Rigorous Auditing: If decentralized processing is unavoidable, sponsors must implement a independent Quality Assurance program to keep track of PBMC quality. This serves as a critical mechanism for onboarding new sites, training new operators or just having confidence that the input samples are meeting the intended standards.
Conclusion
Data harmonization starts at the centrifuge. By controlling the isolation variable—or strictly auditing it—you ensure that any differences you see in the data are due to the drug, not the operator.
Planning a multi-site study? Start your project by scoping your study with us to design a robust sample management plan tailored to your clinical sites.